MiniMed Group (MMED) Financials

MiniMed Group’s latest results show a company that is still growing revenue, but profitability and cash generation remain under pressure. In the most recent quarter, revenue rose to $790 million from $687 million a year earlier, while the company still reported a net loss of $119 million attributable to common shareholders. That means growth is happening, but it has not yet translated into consistent earnings.

Margins were also mixed. Gross profit improved to $362 million from $395 million a year ago because cost of revenue rose faster than sales. Operating expenses remained heavy, especially SG&A of $309 million and R&D of $114 million, which pushed the company to an operating loss of $100 million in Q3 2026. By comparison, the prior-year quarter posted operating income of $21 million, so profitability has clearly deteriorated.

Cash flow tells a similarly cautious story. For Q4 2026, MiniMed generated negative operating cash flow of $170 million and negative free cash flow after $56 million of capital spending. The company did finish the quarter with a $286 million increase in cash and equivalents, but that was driven by $512 million in financing cash inflows, not by operations. In other words, balance sheet funding, not business cash generation, powered the cash build.

The balance sheet has meaningful resources, but also large noncurrent assets tied to acquisitions and intangible value. As of Q3 2026, MiniMed reported $4.343 billion in assets, including $2.256 billion of goodwill and $113 million of intangibles. Cash was modest at $10 million, while current liabilities totaled $696 million. The company’s total equity of $3.462 billion provides a sizable book-value cushion, but investors should keep an eye on the quality of those assets and the reliance on financing.

• Revenue growth remains solid, with quarterly sales increasing to $790 million from $687 million year over year.
• Operating cash flow improved sharply versus the prior-year quarter, moving to negative $170 million from a weaker result in the current period’s comparable cash-flow data trend, though it remains negative.
• The company ended the latest reported quarter with a large cash increase of $286 million, strengthening near-term liquidity.
• Equity remains substantial at $3.462 billion, giving the balance sheet a meaningful capital base.
• Gross profit rose in dollar terms, but not enough to offset faster growth in operating costs.
• R&D spending remains elevated at $114 million, which may support future product development but keeps pressure on earnings.
• Goodwill is large relative to total assets, so future impairment risk is something investors should monitor.
• The company is still unprofitable, with a $119 million loss attributable to common shareholders in Q3 2026.
• Operating income swung from a profit to a loss, falling to negative $100 million from positive $21 million a year earlier.
• Operations are burning cash, and the latest cash build was driven by financing rather than core business performance.

Overall, MiniMed looks like a growth story with weak current profitability. Investors will likely want to see whether revenue growth can continue while cost discipline improves, because without a margin turnaround, the company may remain dependent on external financing to support its expansion.